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ABSTRACT 
Objective: Quinoxaline derivatives were reported with wide range of biological activities. Hence it was planned to synthesize and screen for their 
anti inflammatory (in vivo) activity.  
Methods: Orthophenylene diamine was reacted with oxalic acid to form quinoxaline 2, 3 dione. Quinoxaline-2, 3 (1H, 4H)-dione was chlorinated by 
using Phosphorousoxytrichloride (POCl3) in dimethyl formamide, to form 2, 3- dichloroquinoxaline. This dichloride compound was reacted with 4 
amino acetophenone in DMF, refluxed for 5 hours to form 1-(4-(3-chloroquinoxalin-2-ylamino) phenyl) ethanone. Similarly 1-(4-(3-
chloroquinoxalin-2-ylamino) phenyl) ethanone was reacted with corresponding aromatic aldehydes to form quinoxaline derived chalcone by 
Claisen Schmidt reaction. Characterization all the compounds was performed by IR, 1H NMR and Mass spectroscopic data and screened for anti- 
inflammatory activity by carrageenan- induced paw edema method. 
Results: The anti inflammatory data suggested that compounds QCAC 2, 6, 8, 9, 10 and 12 showed significant activity and rest of the compounds 
exhibited moderate activity compared to the standard compound 
Conclusion: The compounds bearing nitro, chloro and methoxy groups have shown prominent activity when compared to compounds without 
these groups. 
Keywords: Quinoxaline, dimethylforamide (DMF), Phosphorousoxytrichloride (POCl3), anti inflammatory activity (in-vivo), diclofenac. 
 
INTRODUCTION 
Recently there has been a lot of interest in quinoxalines, nitrogen 
containing heterocyclic compounds because of their extensive 
biological activities. Qunioxaline is formed by fusing benzene ring 
with diazine to form quinoxaline. The synthesis and chemistry of 
quinoxalines have attracted considerable attention in the past ten 
years [1]. Some of them exhibited biological activities including anti-
inflammatory[2], anti-bacterial[3], anti-tumor[4],anti-HIV[5],AMPA 
antagonist [6], anti-tubercular[7], and neuro pharmacological 
agent[8], 5-HT3 antagonism. They are also used in the agricultural 
field as fungicides, herbicides, and insecticides [12].  
Also, quinoxaline moiety is present in the structure of various 
antibiotics such as echinomycin, levomycin and actinoleutin, which 
are known to inhibit the growth of gram positive bacteria and they 
are active against various transplantable tumor[13]. In addition, 
quinoxaline derivatives also found applications in dyes[14], efficient 
electron luminescent materials[15], organic semiconductors[16], 
chemically controllable switches[17], building blocks for the 
synthesis of anion receptors[18], cavitands[19], and 
dehydroannulenes[20]. They also serve as useful rigid subunits in 
macrocyclic receptors in molecular recognition. Hence in the light of 
extensive applications, it was planned to synthesize a new series of 
quinoxaline derivatives and screen for their anti- inflammatory 
activity. 
MATERIALS AND METHODS 
Orthophenylenediamine, phosphrousoxytrichloride, oxalic acid 
dimethylsulfoxide(DMSO), 4 amino acetophenone, 
dimethylformamide(DMF), hydrochloric acid, chloroform, hexane, 
ethanol were used for the synthesis of quinoxalines. The following 
experimental methods were used for the characterization of the 
synthesized compounds. Melting points of the synthesized 
compounds were determined in open capillary tubes and are 
uncorrected. The IR spectrum was recorded on ELICIO FTIR 
spectrometer using potassium bromide pellets. 1H-NMR spectra of 
the compounds in deutiriated dimethylsulfoxide was recorded on 
BRUKER Av 400 MHz spectrometer. Mass spectrum was recorded on 
GCMS QP 5000 shimadzu. Thin layer chromatography was 
performed using precoated aluminium plates coated with silica gel 
GF254 [E. Merck]. N-hexane: ethyl acetate was used as the eluent. The 
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Synthesis of quinoxaline derivatives 
Synthesis of 1, 4-dihydro quinoxaline-2, 3-dione 
A solution of oxalic acid dihydrate (0.238 mole, 30g) in H2O (100 ml) 
was heated to 100°C and 4.5 ml of concentrated hydrochloric acid 
was added, followed by O-phenylenediamine (0.204 mole, 22g) with 
stirring, temperature was maintained at 100 °C for 20 min. 
Completion of the reaction was confirmed by TLC. The mixture was 
cooled by addition of ice. The precipitate formed was washed with 
water and recrystalized from ethanol. 
Synthesis of 2, 3 dichloro quinoxaline 
A mixture of quinoxaline-2,3-dione (16.2 g, 0.1 mole), freshly 
distilled phosphorous oxy trichloride (POCl3, 60 mL) and N,N-
Dimethyl formamide (DMF, 5 mL) was refluxed with stirring for 1.5 
hrs. Completion of the reaction was confirmed by TLC. The cooled 
reaction mixture was slowly poured into ice-water with stirring and 
the resulting solid was filtered, washed with water, dried and 
recrystallized from a mixture of chloroform and n-Hexane. 
Synthesis of 1-(4-(3-chloroquinoxalin-2-ylamino)phenyl) ethanone 
4-Aminoacetophenone (8.2 g 0.01 mole) and 2, 3 dichloro 
quinoxaline were dissolved in N, N- Dimethylformamide (40 ml). 
The reaction mixture was refluxed for 5 hours, cooled and poured 
into crushed ice. Periodically, sodium carbonate solution (0.005, 
0.53g in 10 ml water) was added to neutralize HCl evolved during 
the reaction. The progress of the reaction was monitored on TLC 
plate. After completion, the solid separated out was filtered, washed 
with water, dried and recrystallized from alcohol to give 1-(4-(3-
Chloroquinoxalin-2-ylamino)phenyl)ethanone. 
Synthesis of quinoxalines derived chalcones  
Equimolar quantities of 1-(4-(3-Chloroquinoxalin-2-yl amino) 
phenyl) ethanone and substituted aldehydes were dissolved in 
alcoholic solution, and then solution of KOH or NaOH (5 ml of 40%) 
was added to the reaction mixture with constant stirring at room 
temperature. After 24 hrs the reaction mixture was neutralized with 
HCl. The product separated out was filtered, washed with water, 
dried and recrystallized from ethanol to give quinoxalines derived 
chalcones.  
Characterization 
Quinoxaline 2,3 (1H,4H) Dione (Q): % yield: 90%; Melting point: 
360-362oc; Rf=0.76 (n-hexane: ethyl acetate) (7:3); IR (KBr) Vmax 
(cm-1): CH 3042.3001; 1HNMR (400 MHz,DMSO D6) (δppm): 11.8-
12.0(s,2H,NH), 7.0-7.1(d,4H, aromatic, j=3.0) mass 
(m/z)=160(100%), 162(M+). 
Dichloro Quinoxalines (QC): % yield: 70%; Melting point: 150-
152oc Rf=0.34 (n-hexane: ethyl acetate)(7:3); IR (KBr) Vmax (cm-1): CH 
2938; 1HNMR (400 MHz,DMSO D6) (δppm): 7.0-7.1(m,4H, aromatic, 
j=3.0) mass(m/z)=190(100%),198(M+). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)Ethanone (QCAC): 
% yield: 75%; Melting point: 294-296oc Rf=0.34 (n-hexane: ethyl 
acetate)(7:3); IR (KBr) Vmax (cm-1): 1594 (C=C),1165(C-NH), 
1674(CH=CH); 1HNMR (400 MHz,DMSO D6)(δppm): 6.8(d,2H, 
CH=CH, j=3.0). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-Phenylprop-2-
En-1-One(1): % yield: 60%; Melting point: 294-296oc Rf=0.34 (n-
hexane: ethyl acetate)(7:3); IR KBr cm-1: 1594 (C=C),1169(C-NH), 
1673(CH=CH); 1HNMR (400 MHz,DMSO D6)(δppm):3.8(d,3H,CH3 
J=4.0), 6.8(d,2H, CH=CH, j=3.0), 7.0-8.4(m,10H,aromatic), 
9.8(s,1H,NH) mass (m/z)=375(100%), 385(M+). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-(4-
Methoxyphenyl)Prop-2-En-1-One(2):% yield: 50%;; Melting 
point: 284-286oc Rf=0.19(n-hexane: ethyl acetate)(8:2); IR (KBr) 
Vmax (cm-1): 1598 (C=C),1177(C-NH), 1670(CH=CH); 1HNMR (400 




Methoxy Phenyl)Prop-2-En-1-One(3): % yield: 58%; Reaction 
time: 18 hours; Melting point: 274-276oc Rf=0.12 (n-hexane: ethyl 
acetate)(6:4); IR (KBr) Vmax (cm-1): 1603 (C=C), 1179 (C-NH), 
1670(CH=CH), (OCH3) 2835; 1HNMR (400 MHz,DMSO 
D6)(δppm):3.8(d,3H, CH3 J=4.0), 6.7(d,2H, CH=CH, j=3.0), 7.2-
8.4(m,12H,aromatic),9.8(s,1H,NH) mass (m/z)=431(100%)(M+). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-(Furan-
2yl)Prop-2-En-1-One(4): % yield: 56.9; m. p(0c):224-226; Rf Vale: 
0.76(n-hexane: ethyl acetate); IR (KBr) Vmax (cm-1):1596.35(C=C), 
3339.26(C-NH), 1667.16(CH=CH); 1HNMR (400Mz,DMSOd6) 
(δppm):3.2-3.3(d,3H,CH3)J =2.4,6.7-6.73(d,2H,CH=CH)J=2.6,7.1-
8.3(m,9H,aromatic),9.9(s,1H,NH);mass (m/z):380(100%)1, 385,386. 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-(2- Nitro 
Phenyl)Prop-2-En-1-One(5): % yield: 52. m. p(0c):208-210OC; Rf 
Value: 0.97(n-hexane: ethyl acetate); IR (KBr) Vmax (cm-1): 
1466.85(C=C),1177.54(C-NH),1618.59(CH=CH); 1HNMR (400Mz, 
DMSOd6) (δppm): 3.43.43 (s, 3H,CH3), 4.4-4.5(s,1H,NO2) 
7.28.4(m,11H,aromatic). 9.8(s,1H,NH), 4-12.5(s, 1H,CH2).13.7 (s, 1H, 
CH2); mass m/z: 174.190,194(100%),430(M+1). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-(4-
Nitrophenyl)Prop-2-En-1-One(6): % yield: 52.7; m. p(0c):208-
210OC; Rf Value: 0.97(n-hexane: ethyl acetate); IR (KBr) Vmax (cm-
1):1466.85(C=C),1177.54 (C-NH),1618.59(CH=CH); 1HNMR (400Mz, 
DMSOd6) (δppm):3.4-3.43(s,3H,CH3),4.4-4.5(s,1H,NO2), 7.28.4 (m,11H, 
aromatic). 9.8(s,1H,NH),4-12.5(s,1H,CH2).13.7 (s,1H,CH2); mass m/z: 
174.190,194(100%),430(M+1). 
3-(2-Chlorophenyl)-1-(4-(3-Chloroquinoxalin-2-
Ylamino)Phenyl)Prop-2-En-1-One(7): % yield: 53.7;m. p(0c):274-
276; Rf Value: 0.114(n-hexane: ethyl acetate); IR (KBr) Vmax (cm-1): 
1482.08(C=C), 1131.13(C-NH), 1621.19(CH=CH); 1HNMR (400MHz 
DMSO d6)(ð ppm): 3.8(singlet 3H,CH3),5.1(d,2H,CH=CH)J=3.6 7.21 
8.3(m, 10H,aromatic),9.7(s,1H,C-NH),10.3-10.4(t,1H,CH2); mass 
(m/z):135,190,247,421(M+1). 
3-(4-Chlorophenyl)-1-(4-(3-Chloroquinoxalin-
2ylamino)Phenyl)Prop-2-En-1-One(8): % yield: 53.7; m. 
p(0c):274-276; Rf Value: 0.114(n-hexane: ethyl acetate); IR (KBr) 
Vmax (cm-1): 1482.08(C=C), 1131.13(C-NH), 1621.19(CH=CH); 




Hydroxyphenyl)Prop-2-En-1-One(9):% yield: 58.7; brown 
crystals; m. p(0c):198-200; Rf Value: 0.27(n-hexane: ethyl acetate); IR 
(KBr) Vmax (cm-1): 1457.85(C=C), 1177.56 (C-NH),1680.91(CH=CH); 
1HNMR (400Mz DMSO d6) (δppm):2.9(S,2H,CH2),3.6(S,3H,CH3),6.8-
6.9(d.2H,CH=CH)J=0.35,7.21-8.3(m,6H,aromatic),9.8(s,1H,NH),10.3-
10.4(s,1H,OH)); Mass (m/z):280,376, 384(100%), 400(M+).  
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-3-(4-
Hydroxyphenyl)Prop-2-En-1-One(10): % yield: 57.7; m. 
p(0c):198-200OC; Rf Value: 0.27, (n-hexane: ethyl acetate); IR (KBr) 
Vmax (cm-1): 1457.85(C=C), 1177.56 (C-NH),1680.91(CH=CH); 
1HNMR(400MHz DMSO d6 (δppm)=.2.9(S,2H,CH2),3.6(S,3H,CH3),6.8-
6.9(d.2H,CH=CH)J=0.35,7.21-8.3(m,6H aromatic),9.8(s,1H,NH),10.3-
10.4(s,1H,OH));mass (m/z)280,376,384(100%),400(M+).  
1-(4)-1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl)-5-Phenylpenta-
2,4-Dien-1-One(11): % yield: 53.7: m. p(0c):298-300;Rf Value: 0.75, (n-
hexane: ethyl acetate);IR IR (KBr) Vmax (cm-
1):1616.17(C=N),1180.57(C-NH),1616.17(CH=CH); 1HNMR 
(400MHzDMSO d6) (δppm)=3.4(S,3H,CH3), 5.6(dd,4H,CH=CH), J=4.07.1-
8.4(m, a10H, aromatic), 9.3(s,1H,NH)MS (m/z):190, 222, 
411(100%)(M+). 
1-(4-(3-Chloroquinoxalin-2-Ylamino)Phenyl) (4(Dimethyl 
amino) Phenyl) Prop-2-En-1-One (12): % yield: 45.4; m. p(0c): 300-
302; Rf Value: 0.54; IR (KBr) Vmax (cm-1):1595. 45(C=C),1174.74(CNH), 
1658.09(CH=CH); 1HNMR (400MHz, DMSO,d6) (δppm): 
3.51,3.8(doublet,6H,CH3)J=3.4,6.(d,2H,CH=CH)J =2.4,7.2-
8.7(m,12H,aromatic),9.2(s,1H,NH); MS (m/z): 428 (100%) (M+). 
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Evaluation of acute oral toxicity 
The protocol of the work was approved by Institutional Animal 
Ethics Committee (IAEC) (1725/GO/a/13/CPCSEA). The acute oral 
toxicity of the synthesized compounds was performed according to 
OECD guidelines 423. In this method the toxicity of the synthesized 
compounds was tested using a step wise procedure, each step using 
3 mice of a single sex. The mice were fasted to dosing (food but not 
water should be with held for 3-4 hrs). Following the period of 
fasting the animals should be weighed and the synthesized 
compounds were administered orally at a dose of 2000 mg/kg body 
weight. Animals were observed individually after dosing at least 
once for the duration of first 30 min; sporadically during the first 24 
hrs with special attention given during the first four hours and daily 
thereafter, for a sum of 14 days 
Anti inflammatory activity (in vivo) 
Carrageenan induced rat hind paw edema method [21]. 
The initial paw volume of each rat was noted by mercury 
displacement method by plethysmometer. Animals in group-1 were 
administered with aqueous solution of DMSO (1 ml), the group-2 
received diclofenac at a dose 25mg/kg body weight. 3-9 groups 
received the test samples after the drug treatment. 1% w/w 
Carrageenan solution (0.1 ml/ paw) was injected subcutaneously 
into planter surface of the left hind paw of the rat. The paw volume 
of rats in control, standard and test groups was measured with the 
help of the plethysmometer during the interval of 30, 
60,120,180,240 minutes after Carrageenan administration. 
Percentage protection (or inhibition) was calculated by using the 
formula 
1. % protection= (1-Vt/Vc) * 100 
Vt = increase the paw volume in the test animal 
Vc = increase the paw volume in the control group 
Statistical analysis 
The results were expressed as MEAN±SEM and were analyzed  
using one way analysis of variance (ANOVA) followed by dunnett's t-
test. The probability of 0.05 or less was considered statistically 
significant  
RESULTS AND DISCUSSION 
Acute toxicity studies 
The synthesized compounds were administered at a dose of 
2000mg/kg in 1% DMSO and observed 14 days for the mortality due 
to acute toxicity. Careful observation was made at least twice a day 
for the effect on CNS, ANS, motor activity, salivation, skin coloration 
and other general signs of toxicity were also observed and recorded. 
Since no sign of toxicity observed at 2000mg/kg to the group 
animals, the LD50 value of the synthesized compounds expected 
2000mg/kg and represented as class 5 (2000mg/kg < 
LD50<2500mg/kg).  
From the toxicity studies the data revealed that all synthesized 
compounds proved to be the non toxic at the tested dose levels and 
well tolerated by the experimental animals as their LD50 wt of values 
2000mg/kg between therefore, the 1/10th of the above dose was 
selected and fixed for the further pharmacological evaluation. 
The anti-inflammatory activity (in vivo) of the compounds (QCAC 1-
12) was evaluated by Carrageenan induced rat paw edema method. 
The compounds were tested at 200mg/kg dose and the results were 
compared with that of diclofenac as reference drug. The results were 
summarized in the table-1; suggested that the anti- inflammatory 
activity of the compounds was in the range of 0.66 to 99.0 % 
inhibition, where as the standard drug diclofenac showed activity of 
38.59% inhibition after four hours. 
Among the compounds, screened for anti-inflammatory activity, 
compounds QCAC 2,6, 8,9,10 and 12 showed maximum anti- 
inflammatory activity 20.5 to 99% inhibition where as rest of the 
compounds showed moderate activity 0.66 to 15.3 % inhibition. The 
inflammation is due to the release of histamine, serotonin and 
prostaglandin. Therefore the anti- inflammatory activity of the 
synthesized compounds may be due to the inhibition of histamine, 
serotonin or prostaglandin synthesis. 
 





Mean ±SEM (Paw Volume in ml) followed by %  inhibition 
0 hr 1 hr 2 hr 3 hr 4 hr 
01 Control 1.48±0.03 1.82±0.04 2.19±0.12 2.28±0.32 2.26±0.26 
02 Standard 1.37±0.14 1.47±0.16 1.51±0.13 1.47±0.13 1.40±0.16 
 (Diclofenac Sodium) 7.43 19.23 31.05 35.24 38.59 
03 QCAC-1 1.18±0.08 1.43±0.14 1.50±0.12 1.39±0.10 1.29±0.10 
  (13.86*) (2.72)  (0.66) (5.04) (7.08) 
04 QCAC-2 1.23±0.13 1.42±0.16 1.82±0.11 1.28±0.24 1.27±0.14 
  (10.21*) (3.40) (20.05*) (12.09*) (9.28) 
05 QCAC-3 1.32±0.10 1.49±0.07 1.68±0.11 1.69±0.18 1.58±0.09  
  (3.64) (1.03)  (11.02) (14.96*) (12.85*) 
06 QCAC-4 1.18±0.09 1.43±0.11 1.54±0.09 1.52±0.10 1.49±0.06 
  (13.86*) (2.72)  (1.68) (3.40) (6.42) 
07 QCAC-5 1.16±0.08 1.32±0.09 1.34±0.1 1.26±0.07 1.24±0.06 
  (15.03*) (10.20*)  (11.25) (14.28*) (11.40) 
08 QCAC-6 1.30±0.013 1.46±0.11 1.69±0.10 1.74±0.09 1.73±0.04 
  (5.10*) (0.68)  (11.92*) (18.36*) (23.57*) 
09 QCAC-7 1.21±0.14 1.35±0.12 1.62±0.11 1.43±0.20 1.39±0.11 
  (11.67*) (8.16)  (7.28) (2.72) (0.71) 
10 QC -8 1.40±0.14 1.83±0.11 1.51±0.12 1.61±0.12 1.47±0.10 
  (2.18) (24.48*)  (99.0*) (9.52) (5.00) 
11 QCAC-9 1.32±0.10 1.57±0.19 1.84±0.13 1.86±0.6 1.81±0.08 
  (3.64) (6.80)  (21.85*) (26.53*) (29.28*) 
12 QCAC-10 1.27±0.14 1.59±0.22 1.73±0.21 1.78±0.22 1.61±0.16 
  (7.29*) (8.163)  (14.56*) (21.08*) (15.07*) 
13 QCAC-11 1.17±0.09 1.35±0.07 1.61±0.13 1.42±0.11 1.25±0.06  
  (14.05*) (8.16) (6.60) (3.40) (10.71) 
14 QCAC-12 1.27±0.14 1.75±0.22 1.73±0.21 1.78±.0.22 1.56±0.1 
  (7.29*) (19.04*) (14.5*) (21.08*) (11.04) 
Note: % inhibition was denoted in the parenthesis  
Pradeep et al. 




The compounds bearing nitro, chloro, hydroxy and methoxy groups 
have shown prominent activity when compared to compounds 
without these groups. It was also confirmed that the groups in para 
position showed better activity when compared to the groups in 
ortho position. Further investigation in this area may help to bring 
more potent drugs.  
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